Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.51
-0.51 (-2.66%)
May 15, 2026, 11:30 AM EDT - Market open

Avalo Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-84.74-78.26-35.13-31.54-41.66-84.38
Depreciation & Amortization
0.230.340.170.160.171.66
Stock-Based Compensation
13.9613.625.853.487.558.17
Other Adjustments
8.799-15.246.477.250.82
Change in Receivables
---0.481.782.88-0.41
Changes in Inventories
---0.020.02-0.04
Changes in Accounts Payable
-0.33-0.15-0.16-2.44-0.490.8
Changes in Accrued Expenses
-0.336.66-1.11-9.05-3.633.25
Changes in Unearned Revenue
----0.090.09-
Changes in Other Operating Activities
1.08-2.68-2.960.531.07-0.76
Operating Cash Flow
-59.69-51.46-49.06-30.68-26.75-70.89
Capital Expenditures
----0.16-0.1-0.11
Sale of Property, Plant & Equipment
---0.03--
Purchases of Investments
-78.29-113.72----
Proceeds from Sale of Investments
21.532----
Other Investing Activities
--0.36---
Investing Cash Flow
-56.22-81.720.36-0.13-0.1-0.11
Long-Term Debt Issued
-----32.9
Long-Term Debt Repaid
----21.24--
Net Long-Term Debt Issued (Repaid)
----21.24-32.9
Issuance of Common Stock
2.5715.56185.0746.29-14.773.86
Repurchase of Common Stock
-1.29-0.51----
Net Common Stock Issued (Repurchased)
1.2815.05185.0746.29-14.773.86
Other Financing Activities
--0.46-9.22---
Financing Cash Flow
15.9914.59175.8525.04-14.7106.76
Net Cash Flow
-99.92-118.59127.15-5.77-41.5535.76
Free Cash Flow
-59.69-51.46-49.06-30.84-26.85-71.01
FCF Margin
-101173.00%-87216.90%-11123.80%-1602.81%-148.72%-1315.39%
Free Cash Flow Per Share
-0.02-3.84-6.54-111.04-96.66-2009.58
Levered Free Cash Flow
-84.09-74.07-39.19-63.81-44.53-46.68
Unlevered Free Cash Flow
-78.67-68.89-72.8-38.39-40.33-77.15
Updated May 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q